This company is also listed in the United States as ONCY on the NASDAQ. Click here to get the live US quote and see if there are any SEC insider filings.. |
Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7 CALGARY AB T2R 0C5 |
Tel: | N/A |
Website: | https://www.oncolyticsbiotech.com |
IR: | See website |
Key People | ||
Matthew C. Coffey President, Chief Executive Officer, Director | Kirk J. Look Chief Financial Officer | Andrew De Guttadauro Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc. |
Allison Hagerman Vice President - Product Development | Thomas C. Heineman Chief Medical Officer of Oncolytics Biotech (U.S.) |
Business Overview |
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company's primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study. |
Financial Overview |
For the fiscal year ended 31 December 2023, Oncolytics Biotech Inc revenues was not reported. Net loss increased 12% to C$27.8M. Higher net loss reflects Foreign exchange (loss) gain decrease from C$1.7M (income) to C$475K (expense), Research and development - Balancing val increase of 25% to C$10.1M (expense), Employee compensation and benefits increase of 16% to C$3.3M (expense). |
Employees: | 29 as of Dec 31, 2022 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $74.12M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$33.39M as of Dec 31, 2023 |
Net annual income (TTM): | -$27.75M as of Dec 31, 2023 |
Free cash flow (TTM): | -$28.46M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 75,419,768 as of Mar 26, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |